BPC-157 5mg research vial
SwissNova Labs
BPC-157 5mg · 5mg
≥99% Purity · COA Included
Recovery

BPC-157 5mg

Purity: 99%+
Size: 5mg
Grade: Research
Form: Lyophilized
SwissNova Labs · Research Grade
RecoveryNEW!

BPC-157 5mg

Body Protection Compound — the gold standard for tendon, ligament, and gut healing.

Tendon & ligament healing — upregulates growth factor receptors and accelerates connective tissue repairAngiogenesis — stimulates new blood vessel formation to improve blood supply to injured tissueGut protection — heals gastric ulcers, IBD, and intestinal permeability (leaky gut)Systemic distribution — effective even when injected away from the injury site
Strength5mg
$40.00
5mg · Research use only
Compound Specifications
Purity99%+
Molecular Weight1419.5 Da
Vial Size5mg
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Vial Supply
Duration~4 weeks supply
Week 1Week 4
Why Researchers Choose This Compound

Key Benefits

01
Tendon & ligament healing

upregulates growth factor receptors and accelerates connective tissue repair

02
Angiogenesis

stimulates new blood vessel formation to improve blood supply to injured tissue

03
Gut protection

heals gastric ulcers, IBD, and intestinal permeability (leaky gut)

04
Systemic distribution

effective even when injected away from the injury site

Mechanism of Action

Active Signaling Pathway

BioHuman Research Dossier
Human Data AvailableResearch use only — not for human consumption

Investigated Pathways

AngiogenesisNitric Oxide SignalingMucosal HealingTendon Repair

Proposed Mechanism

BPC-157 promotes healing through multiple pathways: it upregulates growth factor receptors (VEGFR2, FGFR), stimulates angiogenesis (new blood vessel formation), activates the nitric oxide system to improve blood flow, and modulates the tendon-to-bone healing cascade. It also exhibits gastroprotective effects by maintaining gut mucosal integrity and modulating the enteric nervous system.

Research Highlights

  • Shown to heal tendon-to-bone injuries 2× faster than controls in rodent models
  • Demonstrated complete healing of severed Achilles tendons in multiple animal studies
  • Gastroprotective effects documented — heals gastric ulcers, IBD, and leaky gut in preclinical models
  • Neuroprotective properties shown in traumatic brain injury and spinal cord injury models
Human Data AvailableEvidence Strength

Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.

Research FocusGut & GI
Gut & GI body system research map
Gut & GILiver

For laboratory research only

All Research Systems →

For research use only — not for human consumption. No treatment claims.

Full Research Hub →
Synergistic Protocols

Recommended Stacks

BPC-157 5mg is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.

Fitness & Performance

Wolverine Recovery Stack

The gold-standard dual-peptide repair protocol — BPC-157 + TB-500 for connective tissue, muscle, and systemic healing.

Most Popular
BPC-157 5mgPrimary — Local tissue & gut repair
Accelerates tendon-to-bone healing, promotes angiogenesis at injury sites, and repairs gut lining. Works best injected close to the area of concern.
6–10 weeksBeginner3 compounds
View Full Stack →
Supply Calculator

How long will one vial last?

Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.

One vial lasts
4
weeks
Approximately 1 month of supply at standard protocol volumes.
Reorder around week 3 to avoid running out
Your supply timeline5mg vial
Start↑ ReorderWeek 4 — empty
1
2
3
4
Active supplyReorder week

Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.

Research Literature

Scientific Background

Mechanism of Action

BPC-157 promotes healing through multiple pathways: it upregulates growth factor receptors (VEGFR2, FGFR), stimulates angiogenesis (new blood vessel formation), activates the nitric oxide system to improve blood flow, and modulates the tendon-to-bone healing cascade. It also exhibits gastroprotective effects by maintaining gut mucosal integrity and modulating the enteric nervous system.

Clinical Context

BPC-157 has over 30 years of preclinical research and is one of the most replicated healing peptides in the literature. It is used in research protocols for musculoskeletal injuries, gut disorders, and neurological recovery. Its systemic effects make it effective even when injected away from the injury site.

Research Highlights

  • Shown to heal tendon-to-bone injuries 2× faster than controls in rodent models
  • Demonstrated complete healing of severed Achilles tendons in multiple animal studies
  • Gastroprotective effects documented — heals gastric ulcers, IBD, and leaky gut in preclinical models
  • Neuroprotective properties shown in traumatic brain injury and spinal cord injury models

Storage & Reconstitution

Peer-Reviewed Research

Key Studies

2018Current Pharmaceutical Design

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

Sikiric P et al.

BPC-157 demonstrated comprehensive healing of tendon-to-bone injuries and gut mucosal damage via VEGFR2 and FAK pathway activation.

PubMed →
2011Regulatory Peptides

Cytoprotective effect of BPC 157 on gastric mucosa

Chang CH et al.

BPC-157 protected gastric mucosa from NSAID-induced damage and accelerated ulcer healing through NO-dependent mechanisms.

PubMed →
2019Current Pharmaceutical Design

BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing

Gwyer D et al.

Comprehensive review confirming BPC-157's systemic healing effects across multiple tissue types via angiogenic and growth factor pathways.

PubMed →
Absorption & Distribution

Pharmacokinetics

PK Parameters
Bioavailability~100% SubQ (peptide absorbed intact)
Peak Plasma30–60 min
Half-life~4 hours SubQ; short half-life supports twice-daily dosing for acute injury protocols
ClearanceHepatic and renal proteolytic clearance
Volume of Distribution~0.3 L/kg
What this means

Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.

The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.

Molecular Targets

Receptor Binding Profile

VEGFR2Upregulation

Promotes angiogenesis and new blood vessel formation at injury sites

FAK/paxillin pathwayActivation

Drives cell migration and proliferation for tissue repair

eNOS / NO synthaseModulation

Increases nitric oxide production, improving local blood flow

EGF receptorUpregulation

Enhances epithelial and mucosal healing

Safety Profile

Side Effects & Adverse Events

Common
  • Mild injection site redness
  • Transient nausea at high doses
Uncommon
  • Dizziness
  • Fatigue
Serious
  • None reported in research literature
NOTE:Excellent safety profile across 30+ years of preclinical research. No serious adverse events reported at any dose tested.
Research Safety

Contraindications & Interactions

Absolute Contraindications
Active malignancy (theoretical — pro-angiogenic effects)
Relative Contraindications
Pregnancy or lactation (insufficient data)Concurrent anticoagulant therapy
Drug Interactions
May potentiate GI-protective effects of NSAIDsTheoretical additive effect with other angiogenic agents
NOTE:No human clinical trials completed. All safety data from animal models. Exercise caution in any oncology context.
Stack Protocols

Synergistic Compounds

TB-500

Complementary repair mechanisms — BPC-157 targets local angiogenesis while TB-500 provides systemic cell migration and anti-inflammatory effects.

BPC-157 250–500 mcg + TB-500 2 mg, both SubQ, daily or every other day for 4–8 weeks.

View Compound →
KPV

KPV's NF-κB inhibition complements BPC-157's gut mucosal healing for IBD and leaky gut research.

BPC-157 250 mcg SubQ + KPV 500 mcg oral or SubQ, once or twice daily.

View Compound →
Sourcing & Testing

Transparent Global Sourcing

🇨🇳

Manufactured

Sourced through our manufacturing partner in China

🧪

Independent Testing

Analytical reports available from Janoshik Analytical

🔍

Batch Verification

Batch-specific COAs with online verification via janoshik.com

🇺🇸

US Fulfillment

Orders fulfilled from the United States

Testing documentation varies by product and batch. Customers may review available reports and verification information before ordering. COA task numbers and verification keys can be confirmed directly at janoshik.com/verification. For research use only — not for human consumption.
RESEARCH USE ONLY:All products are sold strictly for in vitro research and laboratory use. Not intended for human consumption, clinical use, diagnosis, treatment, or prevention of any disease or condition. By purchasing, you confirm you are a qualified researcher and will use these compounds in accordance with all applicable laws and regulations.